Sustainability and affordability of cancer drugs: a novel pricing model

The affordability of newly approved anticancer agents is a challenge to many national health services and reimbursement systems. Therefore, we have developed an approach based upon the adoption of a novel model of price setting and herein provide examples of how it might be implemented. This model is intended to alter the balance between social and economic entrepreneurship.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Outline of a proposed new pricing model for cancer drugs.


  1. 1.

    International Agency for Research on Cancer & World Health Organization. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. IARC (2017).

  2. 2.

    Luengo-Fernandez, R. et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14, 1165–1174 (2013).

    Article  PubMed  Google Scholar 

  3. 3.

    Davis, C. et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–2013. BMJ 359, j4530 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Chandra, A., Shafrin, J. & Dhawan, R. Utility of cancer value frameworks for patients, payers, and physicians. JAMA. 315, 2069–2070 (2016).

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    OncLive. Enzalutamide pricing debate goes to Washington. OncLive (2016).

  6. 6.

    Orphan Druganaut Blog. What is the price of orphan drug ruxolitinib? Orphan Druganaut Blog (2012).

  7. 7.

    DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Prasad, V. & Mailankody, S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern. Med. 177, 1569–1575 (2017).

    Article  PubMed  Google Scholar 

  9. 9.

    Marseille, E. et al. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull. World Health Organ. 93, 118–124 (2015).

    Article  PubMed  Google Scholar 

  10. 10.

    American Society of Clinical Oncology. American Society of Clinical Oncology position statement on addressing the affordability of cancer drugs. ASCO (2017).

Download references

Author information



Corresponding author

Correspondence to Carin A. Uyl-de Groot.

Ethics declarations

Competing interests

C.U.-d.G. has received unrestricted grants for research within the Erasmus University from Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Genzyme, Gilead, Janssen-Cilag, Merck, Roche and Sanofi. B.L. has received personal fees from Agros Pharmaceuticals, Astellas, ASTEX, Celgene, Clear Creek Bio, F. Hoffman-La Roche, Novartis and Seattle Genetics.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Uyl-de Groot, C.A., Löwenberg, B. Sustainability and affordability of cancer drugs: a novel pricing model. Nat Rev Clin Oncol 15, 405–406 (2018).

Download citation

Further reading